|
Synonyms: CDP-835 | CDP835 | Cinqaero® | Cinqair® | JES1-39D10 | SCH55700
reslizumab is an approved drug (EMA & FDA (2016))
Compound class:
Antibody
|
| Immunopharmacology Comments |
| Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. Consequently survival and activity of eosinophils are reduced, lowering exacerbation rates and improving lung function in patients with severe eosinophilic asthma. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Asthma |
Disease Ontology:
DOID:2841 OMIM: 600807 |
Approved therapeutic as maintenance treatment for asthma in combination with other asthma medications. | |